Kezdőlap › Tüdőrák › Washington › Seattle
Tüdőrák klinikai vizsgálatok: Seattle, WA
33 Tüdőrák vizsgálat keres résztvevőket Seattle és környéke (kb. 30 mérföldes körzetben) helyszínein. Nyissa meg a vizsgálatot, hogy lássa, ki csatlakozhat, és hogyan léphet kapcsolatba a csapattal.
Hivatalos vizsgálati szöveg (angol)
Vizsgálatra keres résztvevőket? Emelje ki az oldal tetején — $99 / 30 nap →
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
Toborzás folyamatban1/2. fázis
- University of Washington, Fred Hutchinson Cancer Center, Seattle
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
Toborzás folyamatbanMegfigyeléses tanulmányEgészséges önkéntesek is jelentkezhetnek
- Swedish Medical Center-Ballard Campus, Seattle
- Swedish Medical Center-Cherry Hill, Seattle
- Swedish Medical Center-First Hill, Seattle
- és további 1
Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial
Toborzás folyamatban3. fázis
- Swedish Medical Center-First Hill, Seattle
Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors
Toborzás folyamatban1. fázis
- Fred Hutchinson Cancer Center, Seattle
Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial
Toborzás folyamatban3. fázis
- Swedish Medical Center-First Hill, Seattle
Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC
Toborzás folyamatban3. fázis
- University of Washington - Fred Hutchinson Cancer Center, Seattle
A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors
Toborzás folyamatban1/2. fázis
- Swedish Medical Center, Seattle
A Study to Compare the Combination of Navlimetostat (BMS-986504) With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion
Toborzás folyamatban2/3. fázis
- Fred Hutchinson Cancer Center, Seattle
Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer
Toborzás folyamatban2. fázis
- Research Site, Seattle
A Restorative Justice-Based Lung Cancer Screening Decision-Making Support Intervention Tailored for Black Individuals to Increase Lung Cancer Screening Among Black Community Members, RESTORE Trial
Toborzás folyamatbanEgészséges önkéntesek is jelentkezhetnek
- Fred Hutch/University of Washington Cancer Consortium, Seattle
Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies
Toborzás folyamatban1/2. fázis
- Fred Hutchinson Cancer Research Center, Seattle
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
Toborzás folyamatban3. fázis
- Swedish Medical Center, Seattle
- VA Puget Sound Health Care System, Seattle
AVENTINE-1: Study of AVZO-1418 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Solid Tumors (AVZO-1418-1001)
Toborzás folyamatban1/2. fázis
- Avenzo Therapeutics Recruiting Site, Seattle
Open-label Study of BBO-8520 in Adult Subjects With KRASG12C Non-small Cell Lung Cancer
Toborzás folyamatban1. fázis
- Fred Hutchinson Cancer Center, Seattle
SX-682 and Atezolizumab for the Treatment of Advanced or Metastatic, Recurrent Non-small Cell Lung Cancer
Toborzás folyamatban2. fázis
- Fred Hutch/University of Washington Cancer Consortium, Seattle
Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung Cancer
Toborzás folyamatban3. fázis
- Virginia Mason Medical Center, Seattle
Hippocampal Avoidance in Craniospinal Irradiation for the Treatment of Leptomeningeal Metastases From Breast Cancer or Non-small Cell Lung Cancer
Toborzás folyamatban2. fázis
- Fred Hutch/University of Washington Cancer Consortium, Seattle
PET/CT Changes During Chemoimmunotherapy and Radiation Therapy in Patients With Stage IV Non-small Cell Lung Cancer
Toborzás folyamatban
- Fred Hutch/University of Washington Cancer Consortium, Seattle
Study Evaluating the Safety and Efficacy of HWK-007, a PTK7-directed Antibody Drug Conjugate in Participants With Advanced Solid Tumors
Toborzás folyamatban1. fázis
- Fred Hutchinson Cancer Center, Seattle
Study of XmAb®819 in Subjects With Advanced Clear Cell Renal Cell Carcinoma
Toborzás folyamatban1. fázis
- Xencor Investigative Site, Seattle
Personalized Neo-Antigen Peptide Vaccine for the Treatment of Stage IIIC-IV Melanoma, Hormone Receptor Positive HER2 Negative Metastatic Refractory Breast Cancer or Stage III-IV Non-Small Cell Lung Cancer
Toborzás folyamatban1. fázis
- Fred Hutch/University of Washington Cancer Consortium, Seattle
A Study of Peluntamig (PT217) in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study)
Toborzás folyamatban1/2. fázis
- Fred Hutch Cancer Center, Seattle
Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC
Toborzás folyamatban1/2. fázis
- Fred Hutchinson Cancer Research Center, Seattle
Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung Cancer
Toborzás folyamatban2. fázis
- Seattle Cancer Care Alliance, Seattle
SX-682 With Pembrolizumab for the Treatment of Metastatic or Recurrent Stage IIIC or IV Non-Small Cell Lung Cancer
Toborzás folyamatban2. fázis
- Fred Hutch/University of Washington Cancer Consortium, Seattle
A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression
Toborzás folyamatban1/2. fázis
- Fred Hutchinson Cancer Center, Seattle
Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)
Toborzás folyamatban2. fázis
- Fred Hutchinson Cancer Center, Seattle
- Swedish Medical Center-First Hill, Seattle
- FHCC at Northwest Hospital, Seattle
- és további 1
Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
Toborzás folyamatban1/2. fázis
- Virginia Mason Medical Center, Seattle
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)
Toborzás folyamatban2. fázis
- Swedish Medical Center-First Hill, Seattle
A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors
Toborzás folyamatban1/2. fázis
- Virginia Mason Medical Center, Seattle
A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation
Toborzás folyamatban1. fázis
- Fred Hutchinson Cancer Center, Seattle
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Toborzás folyamatbanMegfigyeléses tanulmány
- Massive Bio SYNERGY-AI site, Seattle
A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression
Toborzás folyamatban1/2. fázis
- Fred Hutch Cancer Center, Seattle
Tüdőrák vizsgálatok más városokban
- Houston, TX78 tanulmány
- Boston, MA62 tanulmány
- New York City, NY60 tanulmány
- Los Angeles, CA45 tanulmány
- Washington, DC41 tanulmány
- Arlington, VA41 tanulmány
- Chicago, IL41 tanulmány
- Nashville, TN40 tanulmány
- Baltimore, MD40 tanulmány
- St. Louis, MO39 tanulmány
- Columbus, OH37 tanulmány
- Philadelphia, PA36 tanulmány
Egyéb vizsgálatok: Seattle
- Nem kis sejtes tüdőrák53 tanulmány
- Rák (minden típus)49 tanulmány
- Prosztatarák42 tanulmány
- Akut mieloid leukémia40 tanulmány
- Mellrák39 tanulmány
- Áttétes rák39 tanulmány
- Kolorektális rák34 tanulmány
- Petefészekrák30 tanulmány
- Multiplex mielóma22 tanulmány
- Myelodysplasticus szindrómák21 tanulmány
- Akut limfoblasztos leukémia21 tanulmány
- Hólyagrák21 tanulmány
Forrás: ClinicalTrials.gov, adatok lekérve: 2026. okt. 5.. Minden vizsgálat saját alkalmassági feltételeket határoz meg; a döntést a vizsgálati csapat hozza meg.